{"url_path":"/sec/zvsa/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-022759-index.html","accession_number":"0001493152-26-022759","cik":"0001859007","ticker":"ZVSA","issuer_name":"ZyVersa Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-022759-index.html","primary_entity_key":"0001859007","primary_entity_name":"ZyVersa Therapeutics, Inc."},"word_count":56,"has_tables":true,"body_markdown":"**ITEM\n5. OTHER INFORMATION.**\n\n \n\n**Insider\nTrading Plans**\n\n** **\n\nDuring\nthe three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted,\nmodified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each\nterm is defined in Item 408(a) of Regulation S-K."}